

B23
cont

and no expression was detected in human fetal or human adult spleen. These data are not fully consistent with Northern blot or PCR data, probably due to the lack of sensitivity in the *in situ* hybridization assay. It is possible that further tissues would show some expression under more sensitive conditions. --

In the paragraph on page 55, lines 26-29, the text has been amended as follows:

B24

-- In this experiment, expression was found in gut-associated lymphoid tissue and developing splenic white pulp in the fetus. Low level expression was seen in the pALS region of normal adult spleen. Although all other tissues were negative, it is possible that low levels of expression could be observed in other tissue types under more sensitive conditions. --

In the paragraph on page 55, lines 32-33, the text has been amended as follows:

B25

-- The following materials have been deposited with the American Type Culture Collection, 10801 University Blvd., Manassas, Virginia, USA (ATCC): --

In the Claims:

Please cancel claims 1-24 and 31-40.

B24

25. (Amended) A chimeric molecule comprising a PRO285 or PRO286 polypeptide fused to a heterologous amino acid sequence .

26. (As filed) The chimeric molecule of claim 25 wherein said heterologous amino acid sequence is an epitope tag sequence.

27. (As filed) The chimeric molecule of claim 26 wherein said heterologous amino acid sequence is a Fc region of an immunoglobulin.

ent C1
B25

28. (Amended) An antibody which specifically binds to a polypeptide encoded by DNA 40021 (SEQ ID NO:2) or DNA42663 (SEQ ID NO:4) .

29. (As filed) The antibody of claim 28 wherein said antibody is a monoclonal antibody.

sub C2

30. (As filed) The antibody of claim 29 capable of blocking the recognition of a Gram-negative or Gram-positive organism by said polypeptide.

Please add the following claims:

-- 41. The chimeric molecule of claim 25, wherein said PRO285 polypeptide comprises amino acid residues 30 to 836 of Fig. 1 (SEQ ID NO:1).

B28
42. The chimeric molecule of claim 25, wherein said PRO285 polypeptide comprises amino acid residues 1 to 836 of Fig. 1 (SEQ ID NO:1).

43. The chimeric molecule of claim 25, wherein said PRO285 polypeptide comprises amino acid residues 1 to 1049 of Fig. 1 (SEQ ID NO:1).

44. The chimeric molecule of claim 25, wherein said PRO286 polypeptide comprises amino acid residues 27 to 825 of Fig. 3 (SEQ ID NO:3).

45. The chimeric molecule of claim 25, wherein said PRO286 polypeptide comprises amino acid residues 1 to 825 of Fig. 3 (SEQ ID NO:3).

46. The chimeric molecule of claim 25, wherein said PRO286 polypeptide comprises amino acid residues 1 to 1041 of Fig. 3 (SEQ ID NO:3).

47. The chimeric molecule of claim 25, wherein said PRO286 polypeptide comprises amino acid residues 1 to 825 and 849 to 1041 of Fig. 3 (SEQ ID NO:3).

GN
48. An isolated antibody which specifically binds to a PRO285 polypeptide consisting of amino acid residues 30 to 836 of Fig. 1 (SEQ ID NO:1).

49. The antibody of claim 48 which is a monoclonal antibody.

50. The antibody of claim 49 which is a chimeric, humanized or human antibody.

51. An isolated antibody which specifically binds to a RO286 polypeptide consisting of amino acid residues 27 to 825 of Fig. 3 (SEQ ID NO:3).

52. The antibody of claim 51 which is a monoclonal antibody.

53. The antibody of claim 52 which is a chimeric, humanized or human antibody. --